Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEOGENOMICS INC Director's Dealing 2026

Feb 24, 2026

32227_dirs_2026-02-24_560c972f-bfc6-4d24-b4d2-0f11070c42cf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2026-02-21

Reporting Person: Olivo Alicia C (EVP, GC & Business Development)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-02-21 Common Stock M 21079 Acquired 96399 Direct
2026-02-21 Common Stock F 8295 Disposed 88104 Direct
2026-02-23 Common Stock M 8443 Acquired 96547 Direct
2026-02-23 Common Stock F 3323 Disposed 93224 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2026-02-21 Restricted Stock Unit $0 M 21079 Disposed Common Stock (21079) Direct
2026-02-23 Restricted Stock Unit $0 M 8443 Disposed Common Stock (8443) Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $19.12 2026-09-30 Common Stock (1046) 1046 Direct
Stock Option (Right to Buy) $27.34 2027-05-01 Common Stock (1024) 1024 Direct
Stock Option (Right to Buy) $48.99 2028-05-01 Common Stock (516) 516 Direct
Stock Option (Right to Buy) $46.10 2028-08-01 Common Stock (1117) 1117 Direct
Stock Option (Right to Buy) $9.45 2029-05-01 Common Stock (22222) 22222 Direct
Stock Option (Right to Buy) $10.05 2029-09-01 Common Stock (46355) 46355 Direct
Stock Option (Right to Buy) $19.65 2030-05-11 Common Stock (36508) 36508 Direct
Restricted Stock Unit $0 Common Stock (6503) 6503 Direct
Performance Stock Unit $0 Common Stock (19508) 19508 Direct
Stock Option (Right to Buy) $16.45 2034-02-23 Common Stock (42344) 42344 Direct
Restricted Stock Unit $0 Common Stock (59382) 59382 Direct
Performance Stock Unit $0 Common Stock (25330) 25330 Direct
Stock Option (Right to Buy) $13.05 2035-02-21 Common Stock (107450) 107450 Direct

Footnotes

F1: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.

F2: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.

F3: On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

F4: Once vested, the shares of common stock are not subject to expiration.

F5: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

F6: On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F7: On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F8: On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F9: On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F10: On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F11: On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.

F12: On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F13: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.

F14: On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.

F15: On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.

F16: On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.

F17: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.

F18: On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.